MA-RENAGADE-THERAPEUTICS
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.
“We are excited to highlight foundational research and development advancements at ASGCT supported by our poster presentation illuminating ReNAgade’s continued work in validating our immune tropic LNP-based delivery systems in NHPs with broad potential applications in oncology and autoimmune diseases,” said Pete Smith, Ph.D., Chief Scientific Officer of ReNAgade. “Additionally, our oral presentation demonstrates a non-viral, all-RNA gene editing system enabling in vivo, exon-sized insertion and probable re-dosing with the goal of higher specificity and a better safety profile when used in the clinical setting. Together, these promising data are another important step in our efforts to innovate beyond the current limitations of RNA medicine.”
Key Highlights from the Abstracts:
- Employed a systematic barcoding screening approach to evaluate and identify engineered lipid nanoparticles (LNP) from a library of 200+ LNPs across multiple structural and chemically distinct classes of ionizable, helper, structural, and hydrophilic lipids. Lead LNP candidate demonstrated ~60% delivery efficiency in total splenic T cells and ~80% delivery efficiency in peripheral blood T cells in non-human primate models.
- Improved retron-mediated target insertion through a combination of retron reverse transcriptase (RT) engineering, non-coding RNA (ncRNA) minimization, chemical modification, and homology-dependent repair manipulation. Combination of retron system optimization and ncRNA engineering led to 2-fold higher 305 base pair insertion and ~40% editing efficiency in hematopoietic stem cells.
ASGCT Annual Meeting Presentation Details:
- TITLE: “Retron Mediated Exon-Sized Genome Insertion Using an All-RNA System”
SESSION TITLE: New Technologies for Gene Targeting and Gene Correction
PRESENTATION TYPE: Oral
ABSTRACT NUMBER: 14
PRESENTER: Inna Shcherbakova, Ph.D., Senior Director, Platform, ReNAgade Therapeutics
DATE AND TIME: Tuesday, May 7, 2024, from 2:15 p.m. - 3:30 p.m. ET
- TITLE: “Novel Immune Tropic LNP-Based mRNA Delivery in Non-Human Primates”
SESSION TITLE: Wednesday Posters: Other Nonviral Delivery
PRESENTATION TYPE: Poster
ABSTRACT NUMBER: 749
PRESENTER: Juliet Crabtree, Ph.D., Associate Principal Scientist, ReNAgade Therapeutics
DATE AND TIME: Wednesday, May 8, 2024, at 12:00 p.m. ET
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422868550/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics28.10.2025 17:34:00 CET | Press release
Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual, transferrable, sublicensable, freedom-to-operate, license for USA, Europe, Latam, Africa and Central Asia with option to expand rights into Asia-Pacific in 2026, covering patents and other intellectual property necessary for development, manufacturing, and sales of the next-generation CoolMPS sequencing platform that will provide faster, cheaper and more accurate whole genome sequencing and other omics tests. The agreement includes payments linked to technology transfer and revenue-based royalties. Swiss Rockets’ future development will focus on advancing CoolMPS products with innovative read barcoding. These innovations will support comprehensive omics testing for advanced genomic research and molecular health monitoring. CoolMPS chemistry provides the most advanced MPS/NGS generating cos
Osmose Acquires Centillion Solutions, Inc. to Expand Its Technical Services Capabilities28.10.2025 15:00:00 CET | Press release
Osmose Utilities, Inc. today announced that it has acquired Centillion Solutions, Inc., a leading engineering services company for the telecommunications industry. Centillion provides fiber optic engineering, design, drafting and geospatial services for Fiber-to-the X (FTTx) and Hybrid Fiber Coax Networks. Founded in 2007, the company has offices in the U.S., Netherlands, UK, Australia, as well as a global design and engineering operation center in India. The acquisition of Centillion Solutions will further position Osmose with the ability to serve as a single vendor of technical services for telecom companies, providing comprehensive turn-key solutions that include pre-design walkout, Outside Plant (OSP) design, make-ready and permitting, and post construction services. “The addition of Centillion expands Osmose’s ability to deliver a complete, end-to-end fiber engineering solution providing customers with one trusted partner for planning, design, and delivery at scale,” said Mike Ada
Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies28.10.2025 14:16:00 CET | Press release
Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies Aims to improve researcher access to disease-relevant cell models Strengthens Merck’s leadership in next-generation biology Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028493228/en/ Merck and Promega will co-develop novel technologies that advance drug discovery. The agreement unites Merck’s strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies. Together, the companies aim to develop assays capable of tracking cellular activity in real time using an innovative reporter system within three-dimensional (3D)
Guidewire Signs Definitive Agreement to Acquire ProNavigator28.10.2025 14:00:00 CET | Press release
AI-powered knowledge management platform puts expertise at the fingertips of every insurance professional CONNECTIONS CONFERENCE--Guidewire (NYSE: GWRE) today announced that it has entered into a definitive agreement to acquire ProNav Technologies Ltd. (d/b/a ProNavigator), a knowledge management platform purpose-built for the P&C insurance industry. ProNavigator delivers precise, context-aware best practice information directly within insurance workflows, helping professionals work faster and more effectively. Its platform captures, connects, and surfaces institutional knowledge across claims, underwriting, and distribution. Used by 34 insurance organizations, including 12 shared customers with Guidewire, ProNavigator helps increase productivity, reduce claim cycle times, personalize customer service, and accelerate employee onboarding. Once the acquisition is complete, Guidewire will integrate ProNavigator’s insurance-trained intelligence across its platform, delivering advanced sear
Rimini Street Introduces Agentic AI ERP in Groundbreaking White Paper28.10.2025 14:00:00 CET | Press release
Rimini Street declares ERP Software dead and unveils Agentic AI ERP, a next generation, transformative ERP technology that delivers innovation faster, better and cheaper with more agility, deployed over existing ERP Software with no required, costly ERP upgrades Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the publication of its latest thought leadership white paper, The Rise of Agentic AI ERP. This landmark document presents a vision and roadmap for the next-generation technology and tools that will eventually replace today’s ERP Software which has become too big, complex, inflexible and expensive to meet the needs of a fast-changing world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028696910/en/ Rimini Street In
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom